Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...
Kipon is now shipping the World’s first 1.65x FF LPL-LPL rear anamorphic adapter. Kipon states that because there are no ...
Both collaborations aim to enhance education, clinical care and research in ophthalmology. Read more at straitstimes.com.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback